<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00092547</url>
  </required_header>
  <id_info>
    <org_study_id>V501-018</org_study_id>
    <secondary_id>2004_084</secondary_id>
    <nct_id>NCT00092547</nct_id>
  </id_info>
  <brief_title>A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)</brief_title>
  <official_title>A Safety and Immunogenicity Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents and Adolescents (Base Study). A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL at 9-18 Years of Age (Extension Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety, tolerability, and immune response of an investigational
      vaccine in preadolescent and adolescent boys and girls for the prevention of Human Papilloma
      Virus (HPV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The original base protocol (V501-018)(NCT00092547) was extended in amendments V501-018-05 and
      -06 to provide 37 months of follow-up. Additionally, subjects in the Placebo Group during the
      base study were given 3 doses of open-label GARDASIL™ (V501) at Months 30, 32, and 36.

      The study was extended again in amendment V501-018-10(NCT00092547), titled &quot;A Long Term
      Immunogenicity, Safety, and Effectiveness Study of GARDASIL (Human Papillomavirus [Types 6,
      11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL at 9-18 Years of
      Age&quot; to allow a follow-up period to Month 126.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 8, 2003</start_date>
  <completion_date type="Actual">June 1, 2015</completion_date>
  <primary_completion_date type="Actual">November 3, 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Serious Adverse Experiences (SAEs) Through Month 18</measure>
    <time_frame>Up to Month 18</time_frame>
    <description>Tolerability as assessed by the number of participants with clinical adverse experiences through Month 18. A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an &quot;other important medical event&quot; based on medical judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting SAEs From Month 18 Through Month 37</measure>
    <time_frame>Month 18 to Month 37</time_frame>
    <description>Tolerability as assessed by the number of participants with clinical adverse experiences from Month 18 through Month 37</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Other (Non-serious) AEs Through Month 18</measure>
    <time_frame>Up to Month 18: Injection site AEs were collected from Days 1-5 and other non-serious AEs from Days 1-15 after any vaccination</time_frame>
    <description>Tolerability as assessed by the number of participants with clinical adverse experiences through Month 18</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 72</measure>
    <time_frame>Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group)</time_frame>
    <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-HPV 6, 11, 16, and 18 at Month 72</measure>
    <time_frame>Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers for Anti-HPV 6, 11, 16, and 18 at Month 96</measure>
    <time_frame>Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Group and 60 Months Post-dose 3 for Extension Group)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 96</measure>
    <time_frame>Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Cohort and 60 Months Post-dose 3 for Extension Group)</time_frame>
    <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers for Anti-HPV 6, 11, 16, and 18 at Month 126</measure>
    <time_frame>Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 126</measure>
    <time_frame>Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group)</time_frame>
    <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting SAEs Related to Study Vaccine or to a Study Procedure in the Long-term Follow-up</measure>
    <time_frame>Month 37 to Month 126</time_frame>
    <description>A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an &quot;other important medical event&quot; based on medical judgment. SAEs considered by the investigator to be possibly, probably, or definitely related to study vaccine or a study procedure were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 1 Postdose 3 (Month 7)</measure>
    <time_frame>Month 7 (1 Month Postdose 3)</time_frame>
    <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 12 Postdose 3 (Month 18).</measure>
    <time_frame>Month 18 (12 Months Post-dose 3)</time_frame>
    <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 18 Postdose 3 (Month 24)</measure>
    <time_frame>Month 24 (18 Months Post-dose 3)</time_frame>
    <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 24 Postdose 3 (Month 30)</measure>
    <time_frame>Month 30 (24 Months Post-dose 3)</time_frame>
    <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 31 Postdose 3 (Month 37).</measure>
    <time_frame>Month 37 (31 Months Post-dose 3)</time_frame>
    <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in the Extension Group Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 1 Postdose 3 of qHPV (Month 37)</measure>
    <time_frame>Month 37 (1 Month Post-dose 3 of qHPV)</time_frame>
    <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 1 Postdose 3 of qHPV Vaccine (Month 7)</measure>
    <time_frame>Month 7 (1 Month Post-dose 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 12 Postdose 3 of qHPV Vaccine (Month 18)</measure>
    <time_frame>Month 18 (Month 12 Post-dose 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 18 Postdose 3 of qHPV Vaccine (Month 24)</measure>
    <time_frame>Month 24 (18 Months Post-dose 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 24 Postdose 3 of qHPV Vaccine (Month 30)</measure>
    <time_frame>Month 30 (24 Months Post-dose 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 31 Postdose 3 of qHPV Vaccine (Month 37)</measure>
    <time_frame>Month 37 (31 Months Post-dose 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers in the Extension Group for Anti-HPV 6, 11, 16, and 18 at Month 1 Postdose 3 of qHPV Vaccine (Month 37)</measure>
    <time_frame>Month 37 (1 Month Post-dose 3 of qHPV)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Incidence of HPV 6/11/16/18-related Persistent Infection and HPV 6/11/16/18-related CIN, AIS, VIN, VaIN, Genital Warts, and Cervical/Vaginal/Vulvar Cancer in Females</measure>
    <time_frame>Up to Month 126</time_frame>
    <description>The HPV types were determined by polymerase chain reaction (PCR) testing. The combined incidence of HPV 6/11/16/18-related persistent infection and HPV 6/11/16/18-related cervical intraepithelial neoplasia (CIN), adenocarcinoma in situ (AIS), vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN), genital warts, and cervical/Vaginal/vulvar cancer was assessed in female participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Incidence of HPV 6/11/16/18-related Persistent Infection and HPV 6/11/16/18-related PIN, Genital Warts, and Penile/Perineal/Perianal Cancer in Males</measure>
    <time_frame>Up to Month 126</time_frame>
    <description>The HPV types were determined by PCR testing. Combined incidence of HPV 6/11/16/18-related persistent infection and HPV 6/11/16/18-related penile/perineal/perianal intraepithelial neoplasia (PIN), genital warts, and penile/perineal/perianal cancer was assessed in male participants.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1781</enrollment>
  <condition>Human</condition>
  <condition>Papillomavirus Infections</condition>
  <arm_group>
    <arm_group_label>qHPV Vaccine in Base Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in Base Study</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Represents participants who were randomized into the Placebo Group, who received three 0.5 mL intramuscular injections of placebo at Day 1, Month 2, and Month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>qHPV Vaccine in Extension Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Represents participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V501</intervention_name>
    <description>0.5 mL intramuscular injection of V501</description>
    <arm_group_label>qHPV Vaccine in Base Study</arm_group_label>
    <arm_group_label>qHPV Vaccine in Extension Study</arm_group_label>
    <other_name>GARDASIL™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>0.5 mL intramuscular injection of placebo</description>
    <arm_group_label>Placebo in Base Study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adolescents and preadolescents with no prior sexual history

        Exclusion Criteria:

          -  Subjects with compromised immune system or have a history of severe allergic reaction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KE, Sings HL, Lukac S, Alvarez FB, Barr E. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007 Mar;26(3):201-9.</citation>
    <PMID>17484215</PMID>
  </reference>
  <reference>
    <citation>Perez G, Lazcano-Ponce E, Hernandez-Avila M, García PJ, Muñoz N, Villa LL, Bryan J, Taddeo FJ, Lu S, Esser MT, Vuocolo S, Sattler C, Barr E. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer. 2008 Mar 15;122(6):1311-8.</citation>
    <PMID>18000825</PMID>
  </reference>
  <results_reference>
    <citation>Ferris D, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Reisinger KS, Mehlsen J, Chatterjee A, Iversen OE, Sings HL, Shou Q, Sausser TA, Saah A. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics. 2014 Sep;134(3):e657-65. doi: 10.1542/peds.2013-4144. Epub 2014 Aug 18.</citation>
    <PMID>25136050</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferris DG, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Mehlsen J, Chatterjee A, Iversen OE, Joshi A, Chu JL, Krick AL, Saah A, Das R. 4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years. Pediatrics. 2017 Dec;140(6). pii: e20163947. doi: 10.1542/peds.2016-3947.</citation>
    <PMID>29167376</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2004</study_first_submitted>
  <study_first_submitted_qc>September 27, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2004</study_first_posted>
  <results_first_submitted>November 3, 2009</results_first_submitted>
  <results_first_submitted_qc>April 9, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 4, 2010</results_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1781 participants were randomized to receive qHPV or Placebo in the Base Study. At month 30, participants who received Placebo in the Base Study were eligible to receive qHPV, and formed the Extension Group. Participants were to be followed for safety and efficacy for up to 10 years.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>qHPV Vaccine in Base Study</title>
          <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6.</description>
        </group>
        <group group_id="P2">
          <title>Placebo in Base Study</title>
          <description>Represents participants who were randomized into the Placebo Group, who received three 0.5 mL intramuscular injections of placebo at Day 1, Month 2, and Month 6.</description>
        </group>
        <group group_id="P3">
          <title>qHPV Vaccine in Extension Study</title>
          <description>Represent participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Base Vaccine Phase (Day 1 to Month 7)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1184"/>
                <participants group_id="P2" count="597"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="1179"/>
                <participants group_id="P2" count="596"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1121"/>
                <participants group_id="P2" count="561"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>per sponsor request: (noncompliant)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet local regulations</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused Vaccination</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Base Follow-up Phase (Month 7 to 18)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1128">Includes participants continuing and who previously discontinued who re-entered the study</participants>
                <participants group_id="P2" count="565">Includes participants continuing and who previously discontinued who re-entered the study</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1108"/>
                <participants group_id="P2" count="551"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject moved</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Base Follow-up Phase (Month 18 to 30)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="964">Includes participants continuing and who previously discontinued who re-entered the study</participants>
                <participants group_id="P2" count="490">Includes participants continuing and who previously discontinued who re-entered the study</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="956"/>
                <participants group_id="P2" count="485"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject moved</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Vaccine Phase (Month 30 to 37)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="956">Includes participants continuing and who previously discontinued who re-entered the study</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="485">Includes participants continuing and who previously discontinued who re-entered the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated in Extension Study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="482"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="933"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="469"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject moved</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long-term Follow-up (Month 42 Visit)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="612">Includes participants continuing and who previously discontinued who re-entered the study</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="308">Includes participants continuing and who previously discontinued who re-entered the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="611"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="308"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long-term Follow-up (Month 72 Visit)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="550">Includes participants continuing and who previously discontinued who re-entered the study</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="276">Includes participants continuing and who previously discontinued who re-entered the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="550"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="276"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Long-term Follow-up (Month 96 Visit)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="508">Includes participants continuing and who previously discontinued who re-entered the study</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="267">Includes participants continuing and who previously discontinued who re-entered the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="508"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="267"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Long-term Follow-up (Month 126 Visit)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="454"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="211"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="454"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="211"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>qHPV Vaccine in Base Study</title>
          <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="B2">
          <title>Placebo in Base Study</title>
          <description>Represents participants who were randomized into the Placebo Group, who received three 0.5 mL intramuscular injections of placebo at Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1184"/>
            <count group_id="B2" value="597"/>
            <count group_id="B3" value="1781"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.9" spread="1.9"/>
                    <measurement group_id="B2" value="11.8" spread="1.9"/>
                    <measurement group_id="B3" value="11.9" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>8 Years of Age and Under</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 to 16 Years of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1184"/>
                    <measurement group_id="B2" value="597"/>
                    <measurement group_id="B3" value="1781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17 Years of Age and Over</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="616"/>
                    <measurement group_id="B2" value="322"/>
                    <measurement group_id="B3" value="938"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="568"/>
                    <measurement group_id="B2" value="275"/>
                    <measurement group_id="B3" value="843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="260"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="716"/>
                    <measurement group_id="B2" value="369"/>
                    <measurement group_id="B3" value="1085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Serious Adverse Experiences (SAEs) Through Month 18</title>
        <description>Tolerability as assessed by the number of participants with clinical adverse experiences through Month 18. A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an &quot;other important medical event&quot; based on medical judgment.</description>
        <time_frame>Up to Month 18</time_frame>
        <population>All participants who were vaccinated according to actual treatment received (qHPV or placebo) and had safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Base Study</title>
            <description>Represents participants who were randomized into the Placebo Group, who received three 0.5 mL intramuscular injections of placebo at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Serious Adverse Experiences (SAEs) Through Month 18</title>
          <description>Tolerability as assessed by the number of participants with clinical adverse experiences through Month 18. A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an &quot;other important medical event&quot; based on medical judgment.</description>
          <population>All participants who were vaccinated according to actual treatment received (qHPV or placebo) and had safety follow-up.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1165"/>
                <count group_id="O2" value="584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting SAEs From Month 18 Through Month 37</title>
        <description>Tolerability as assessed by the number of participants with clinical adverse experiences from Month 18 through Month 37</description>
        <time_frame>Month 18 to Month 37</time_frame>
        <population>All participants who were vaccinated according to actual treatment received (qHPV or placebo) and had safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine in Extension Study</title>
            <description>Represent participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting SAEs From Month 18 Through Month 37</title>
          <description>Tolerability as assessed by the number of participants with clinical adverse experiences from Month 18 through Month 37</description>
          <population>All participants who were vaccinated according to actual treatment received (qHPV or placebo) and had safety follow-up.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="923"/>
                <count group_id="O2" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Other (Non-serious) AEs Through Month 18</title>
        <description>Tolerability as assessed by the number of participants with clinical adverse experiences through Month 18</description>
        <time_frame>Up to Month 18: Injection site AEs were collected from Days 1-5 and other non-serious AEs from Days 1-15 after any vaccination</time_frame>
        <population>All participants who were vaccinated according to actual treatment received (qHPV or placebo) and had safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Base Study</title>
            <description>Represents participants who were randomized into the Placebo Group, who received three 0.5 mL intramuscular injections of placebo at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Other (Non-serious) AEs Through Month 18</title>
          <description>Tolerability as assessed by the number of participants with clinical adverse experiences through Month 18</description>
          <population>All participants who were vaccinated according to actual treatment received (qHPV or placebo) and had safety follow-up.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1165"/>
                <count group_id="O2" value="584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="918"/>
                    <measurement group_id="O2" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 72</title>
        <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
        <time_frame>Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group)</time_frame>
        <population>Per-protocol population: participants without protocol violations who received all 3 vaccinations, were seronegative to the respective HPV type at Day 1 (for the Base Vaccination group), or Month 30 (for the Extension Group), and had a valid serology result at the specified time for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine in Extension Study</title>
            <description>Represent participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 72</title>
          <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
          <population>Per-protocol population: participants without protocol violations who received all 3 vaccinations, were seronegative to the respective HPV type at Day 1 (for the Base Vaccination group), or Month 30 (for the Extension Group), and had a valid serology result at the specified time for assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="550"/>
                <count group_id="O2" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 6: n=475, 151</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" lower_limit="90.6" upper_limit="95.3"/>
                    <measurement group_id="O2" value="91.4" lower_limit="85.7" upper_limit="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 11: n=475, 151</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="93.8" upper_limit="97.6"/>
                    <measurement group_id="O2" value="96.7" lower_limit="92.4" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 16: n=473, 154</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="96.1" upper_limit="99.0"/>
                    <measurement group_id="O2" value="97.4" lower_limit="93.5" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 18: n=477, 160</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" lower_limit="70.3" upper_limit="78.3"/>
                    <measurement group_id="O2" value="79.4" lower_limit="72.3" upper_limit="85.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) for Anti-HPV 6, 11, 16, and 18 at Month 72</title>
        <time_frame>Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group)</time_frame>
        <population>Per-protocol population: participants without protocol violations who received all 3 vaccinations within appropriate day ranges as defined in the CSR, were seronegative to the respective HPV type at Day 1 (for the Main Vaccination group), or Month 30 (for the Extension Group), and had a valid serology result at the specified time for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine in Extension Study</title>
            <description>Represent participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Anti-HPV 6, 11, 16, and 18 at Month 72</title>
          <population>Per-protocol population: participants without protocol violations who received all 3 vaccinations within appropriate day ranges as defined in the CSR, were seronegative to the respective HPV type at Day 1 (for the Main Vaccination group), or Month 30 (for the Extension Group), and had a valid serology result at the specified time for assessment.</population>
          <units>milliMerck units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="550"/>
                <count group_id="O2" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 6: n=475, 151</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.9" lower_limit="108.4" upper_limit="130.4"/>
                    <measurement group_id="O2" value="113.9" lower_limit="95.7" upper_limit="135.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 11: n=475, 151</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.7" lower_limit="122.6" upper_limit="150.3"/>
                    <measurement group_id="O2" value="137.9" lower_limit="114.9" upper_limit="165.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 16: n=473, 154</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="521.2" lower_limit="466.2" upper_limit="582.6"/>
                    <measurement group_id="O2" value="485.8" lower_limit="396.4" upper_limit="595.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 18: n=477, 160</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9" lower_limit="61.8" upper_limit="81.4"/>
                    <measurement group_id="O2" value="67.7" lower_limit="53.1" upper_limit="86.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers for Anti-HPV 6, 11, 16, and 18 at Month 96</title>
        <time_frame>Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Group and 60 Months Post-dose 3 for Extension Group)</time_frame>
        <population>Per-protocol population: participants without protocol violations who received all 3 vaccinations within appropriate day ranges as defined in the CSR, were seronegative to the respective HPV type at Day 1 (for the Main Vaccination group), or Month 30 (for the Extension Group), and had a valid serology result at the specified time for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine in Extension Study</title>
            <description>Represent participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers for Anti-HPV 6, 11, 16, and 18 at Month 96</title>
          <population>Per-protocol population: participants without protocol violations who received all 3 vaccinations within appropriate day ranges as defined in the CSR, were seronegative to the respective HPV type at Day 1 (for the Main Vaccination group), or Month 30 (for the Extension Group), and had a valid serology result at the specified time for assessment.</population>
          <units>milliMerck units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="508"/>
                <count group_id="O2" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 6: n=451, 141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="64.6" upper_limit="79.0"/>
                    <measurement group_id="O2" value="91.0" lower_limit="76.4" upper_limit="108.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 11: n=451, 141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5" lower_limit="60.1" upper_limit="75.7"/>
                    <measurement group_id="O2" value="90.3" lower_limit="74.0" upper_limit="110.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 16: n=447, 143</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="325.5" lower_limit="288.6" upper_limit="367.1"/>
                    <measurement group_id="O2" value="387.4" lower_limit="314.7" upper_limit="476.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 18: n=452, 152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6" lower_limit="36.5" upper_limit="47.5"/>
                    <measurement group_id="O2" value="48.3" lower_limit="37.6" upper_limit="62.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 96</title>
        <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
        <time_frame>Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Cohort and 60 Months Post-dose 3 for Extension Group)</time_frame>
        <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1 (for the Main Vaccination group), or Month 30 (for the Extension Group), and had a valid serology result at the specified time for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine in Extension Study</title>
            <description>Represent participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 96</title>
          <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
          <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1 (for the Main Vaccination group), or Month 30 (for the Extension Group), and had a valid serology result at the specified time for assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="508"/>
                <count group_id="O2" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 6: n=451, 141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.2" lower_limit="84.9" upper_limit="91.1"/>
                    <measurement group_id="O2" value="91.5" lower_limit="85.6" upper_limit="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 11: n=451, 141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.1" lower_limit="85.9" upper_limit="91.9"/>
                    <measurement group_id="O2" value="93.6" lower_limit="88.2" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 16: n=447, 143</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.9" lower_limit="94.8" upper_limit="98.3"/>
                    <measurement group_id="O2" value="97.9" lower_limit="94.0" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 18: n=452, 152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9" lower_limit="59.3" upper_limit="68.4"/>
                    <measurement group_id="O2" value="69.1" lower_limit="61.1" upper_limit="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers for Anti-HPV 6, 11, 16, and 18 at Month 126</title>
        <time_frame>Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group)</time_frame>
        <population>Per-protocol population: participants without protocol violations who received all 3 vaccinations within appropriate day ranges as defined in the CSR, were seronegative to the respective HPV type at Day 1 (for the Main Vaccination group), or Month 30 (for the Extension Group), and had a valid serology result at the specified time for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine in Extension Study</title>
            <description>Represent participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers for Anti-HPV 6, 11, 16, and 18 at Month 126</title>
          <population>Per-protocol population: participants without protocol violations who received all 3 vaccinations within appropriate day ranges as defined in the CSR, were seronegative to the respective HPV type at Day 1 (for the Main Vaccination group), or Month 30 (for the Extension Group), and had a valid serology result at the specified time for assessment.</population>
          <units>milliMerck units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="454"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 6: n=409, 112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.0" lower_limit="78.9" upper_limit="98.2"/>
                    <measurement group_id="O2" value="99.3" lower_limit="81.0" upper_limit="121.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 11: n=409, 112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" lower_limit="66.1" upper_limit="84.1"/>
                    <measurement group_id="O2" value="96.0" lower_limit="76.1" upper_limit="121.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 16: n=403, 115</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320.1" lower_limit="281.2" upper_limit="364.4"/>
                    <measurement group_id="O2" value="351.6" lower_limit="277.1" upper_limit="446.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 18: n=408, 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" lower_limit="31.7" upper_limit="42.1"/>
                    <measurement group_id="O2" value="39.6" lower_limit="30.7" upper_limit="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 126</title>
        <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
        <time_frame>Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group)</time_frame>
        <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1 (for the Main Vaccination group), or Month 30 (for the Extension Group), and had a valid serology result at the specified time for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine in Extension Study</title>
            <description>Represent participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 126</title>
          <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
          <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1 (for the Main Vaccination group), or Month 30 (for the Extension Group), and had a valid serology result at the specified time for assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="454"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 6: n=409, 112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.0" lower_limit="85.6" upper_limit="91.9"/>
                    <measurement group_id="O2" value="91.1" lower_limit="84.2" upper_limit="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 11: n=409, 112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.8" lower_limit="85.3" upper_limit="91.6"/>
                    <measurement group_id="O2" value="92.9" lower_limit="86.4" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 16: n=403, 115</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="93.6" upper_limit="97.7"/>
                    <measurement group_id="O2" value="96.5" lower_limit="91.3" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 18: n=408, 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5" lower_limit="55.6" upper_limit="65.3"/>
                    <measurement group_id="O2" value="65.0" lower_limit="55.8" upper_limit="73.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting SAEs Related to Study Vaccine or to a Study Procedure in the Long-term Follow-up</title>
        <description>A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an &quot;other important medical event&quot; based on medical judgment. SAEs considered by the investigator to be possibly, probably, or definitely related to study vaccine or a study procedure were reported.</description>
        <time_frame>Month 37 to Month 126</time_frame>
        <population>The analysis population was all participants who were vaccinated according to actual treatment received and had safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine in Extension Study</title>
            <description>Represent participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting SAEs Related to Study Vaccine or to a Study Procedure in the Long-term Follow-up</title>
          <description>A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an &quot;other important medical event&quot; based on medical judgment. SAEs considered by the investigator to be possibly, probably, or definitely related to study vaccine or a study procedure were reported.</description>
          <population>The analysis population was all participants who were vaccinated according to actual treatment received and had safety follow-up.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="821"/>
                <count group_id="O2" value="424"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 1 Postdose 3 (Month 7)</title>
        <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
        <time_frame>Month 7 (1 Month Postdose 3)</time_frame>
        <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 1 Postdose 3 (Month 7)</title>
          <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
          <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1082"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 6: n=953</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="99.2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 11: n=954</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="99.2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 16: n=949</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" lower_limit="99.1" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 18: n=956</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" lower_limit="99.1" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 12 Postdose 3 (Month 18).</title>
        <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
        <time_frame>Month 18 (12 Months Post-dose 3)</time_frame>
        <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 12 Postdose 3 (Month 18).</title>
          <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
          <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 6: n=937</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="96.6" upper_limit="98.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 11: n=938</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="98.5" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 16: n=933</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="98.9" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 18: n=940</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.6" lower_limit="89.6" upper_limit="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 18 Postdose 3 (Month 24)</title>
        <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
        <time_frame>Month 24 (18 Months Post-dose 3)</time_frame>
        <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 18 Postdose 3 (Month 24)</title>
          <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
          <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="595"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 6: n=446</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1" lower_limit="92.6" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 11: n=447</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="96.5" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 16: n=442</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" lower_limit="96.8" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 18: n=447</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="84.0" upper_limit="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 24 Postdose 3 (Month 30)</title>
        <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
        <time_frame>Month 30 (24 Months Post-dose 3)</time_frame>
        <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 24 Postdose 3 (Month 30)</title>
          <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
          <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="911"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 6: n=799</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6" lower_limit="94.0" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 11: n=800</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" lower_limit="96.2" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 16: n=795</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="97.5" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 18: n=803</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.3" lower_limit="81.6" upper_limit="86.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 31 Postdose 3 (Month 37).</title>
        <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
        <time_frame>Month 37 (31 Months Post-dose 3)</time_frame>
        <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 31 Postdose 3 (Month 37).</title>
          <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
          <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="772"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 6: n=657</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" lower_limit="92.5" upper_limit="96.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 11: n=657</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="94.3" upper_limit="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 16: n=655</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="96.8" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 18: n=660</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1" lower_limit="77.9" upper_limit="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in the Extension Group Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 1 Postdose 3 of qHPV (Month 37)</title>
        <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
        <time_frame>Month 37 (1 Month Post-dose 3 of qHPV)</time_frame>
        <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Month 30, and had a valid serology result at the specified time for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Extension Study</title>
            <description>Represent participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in the Extension Group Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 1 Postdose 3 of qHPV (Month 37)</title>
          <description>A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.</description>
          <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Month 30, and had a valid serology result at the specified time for assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 6: n=246</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 11: n=246</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 16: n=246</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 18: n=255</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="96.6" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 1 Postdose 3 of qHPV Vaccine (Month 7)</title>
        <time_frame>Month 7 (1 Month Post-dose 3)</time_frame>
        <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 1 Postdose 3 of qHPV Vaccine (Month 7)</title>
          <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
          <units>milliMerck units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1082"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 6: n=953</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="929.2" lower_limit="871.0" upper_limit="991.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 11: n=954</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1362.8" lower_limit="1279.8" upper_limit="1451.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 16: n=949</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5512.7" lower_limit="5109.9" upper_limit="5947.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 18: n=956</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1278.9" lower_limit="1183.2" upper_limit="1382.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 12 Postdose 3 of qHPV Vaccine (Month 18)</title>
        <time_frame>Month 18 (Month 12 Post-dose 3)</time_frame>
        <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 12 Postdose 3 of qHPV Vaccine (Month 18)</title>
          <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
          <units>milliMerck units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 6: n=937</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.3" lower_limit="204.9" upper_limit="234.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 11: n=938</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296.9" lower_limit="276.9" upper_limit="318.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 16: n=933</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1314.8" lower_limit="1220.5" upper_limit="1416.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 18: n=940</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203.0" lower_limit="184.1" upper_limit="223.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 18 Postdose 3 of qHPV Vaccine (Month 24)</title>
        <time_frame>Month 24 (18 Months Post-dose 3)</time_frame>
        <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represent participants randomized to the qHPV vaccine group</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 18 Postdose 3 of qHPV Vaccine (Month 24)</title>
          <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
          <units>milliMerck units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="595"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 6: n=446</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.5" lower_limit="129.2" upper_limit="159.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 11: n=447</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.6" lower_limit="186.9" upper_limit="228.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 16: n=442</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="932.1" lower_limit="833.3" upper_limit="1042.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 18: n=447</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.2" lower_limit="118.5" upper_limit="156.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 24 Postdose 3 of qHPV Vaccine (Month 30)</title>
        <time_frame>Month 30 (24 Months Post-dose 3)</time_frame>
        <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 24 Postdose 3 of qHPV Vaccine (Month 30)</title>
          <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
          <units>milliMerck units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="911"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 6: n=799</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.5" lower_limit="135.6" upper_limit="158.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 11: n=800</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.0" lower_limit="163.6" upper_limit="191.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 16: n=795</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="826.1" lower_limit="757.8" upper_limit="900.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 18: n=803</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.7" lower_limit="102.8" upper_limit="127.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 31 Postdose 3 of qHPV Vaccine (Month 37)</title>
        <time_frame>Month 37 (31 Months Post-dose 3)</time_frame>
        <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 31 Postdose 3 of qHPV Vaccine (Month 37)</title>
          <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations, were seronegative to the respective HPV type at Day 1, and had a valid serology result at the specified time for assessment.</population>
          <units>milliMerck units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="772"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 6: n=657</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.6" lower_limit="118.2" upper_limit="139.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 11: n=657</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.7" lower_limit="137.0" upper_limit="163.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 16: n=655</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="680.4" lower_limit="617.2" upper_limit="750.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 18: n=660</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.4" lower_limit="90.9" upper_limit="115.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers in the Extension Group for Anti-HPV 6, 11, 16, and 18 at Month 1 Postdose 3 of qHPV Vaccine (Month 37)</title>
        <time_frame>Month 37 (1 Month Post-dose 3 of qHPV)</time_frame>
        <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations within appropriate day ranges, were seronegative to the respective HPV type at Month 30, and had a valid serology result at the specified time for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Extension Study</title>
            <description>Represent participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers in the Extension Group for Anti-HPV 6, 11, 16, and 18 at Month 1 Postdose 3 of qHPV Vaccine (Month 37)</title>
          <population>Per-protocol population: participants without protocol violations who received all 3 qHPV vaccinations within appropriate day ranges, were seronegative to the respective HPV type at Month 30, and had a valid serology result at the specified time for assessment.</population>
          <units>milliMerck units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 6: n=246</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="768.6" lower_limit="676.6" upper_limit="873.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 11: n=246</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1041.0" lower_limit="919.8" upper_limit="1178.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 16: n=246</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4312.7" lower_limit="3715.6" upper_limit="5005.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 18: n=255</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="830.1" lower_limit="714.0" upper_limit="965.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Combined Incidence of HPV 6/11/16/18-related Persistent Infection and HPV 6/11/16/18-related CIN, AIS, VIN, VaIN, Genital Warts, and Cervical/Vaginal/Vulvar Cancer in Females</title>
        <description>The HPV types were determined by polymerase chain reaction (PCR) testing. The combined incidence of HPV 6/11/16/18-related persistent infection and HPV 6/11/16/18-related cervical intraepithelial neoplasia (CIN), adenocarcinoma in situ (AIS), vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN), genital warts, and cervical/Vaginal/vulvar cancer was assessed in female participants.</description>
        <time_frame>Up to Month 126</time_frame>
        <population>Per-Protocol Effectiveness population: male participants without protocol violations who received at least 1 dose of qHPV vaccine and at least 1 effectiveness follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine in Extension Study</title>
            <description>Represent participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Combined Incidence of HPV 6/11/16/18-related Persistent Infection and HPV 6/11/16/18-related CIN, AIS, VIN, VaIN, Genital Warts, and Cervical/Vaginal/Vulvar Cancer in Females</title>
          <description>The HPV types were determined by polymerase chain reaction (PCR) testing. The combined incidence of HPV 6/11/16/18-related persistent infection and HPV 6/11/16/18-related cervical intraepithelial neoplasia (CIN), adenocarcinoma in situ (AIS), vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN), genital warts, and cervical/Vaginal/vulvar cancer was assessed in female participants.</description>
          <population>Per-Protocol Effectiveness population: male participants without protocol violations who received at least 1 dose of qHPV vaccine and at least 1 effectiveness follow-up visit.</population>
          <units>Cases per 100 person-years at risk</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.1" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.0" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Combined Incidence of HPV 6/11/16/18-related Persistent Infection and HPV 6/11/16/18-related PIN, Genital Warts, and Penile/Perineal/Perianal Cancer in Males</title>
        <description>The HPV types were determined by PCR testing. Combined incidence of HPV 6/11/16/18-related persistent infection and HPV 6/11/16/18-related penile/perineal/perianal intraepithelial neoplasia (PIN), genital warts, and penile/perineal/perianal cancer was assessed in male participants.</description>
        <time_frame>Up to Month 126</time_frame>
        <population>Per-Protocol Effectiveness population: male participants without protocol violations who received at least 1 dose of qHPV vaccine and at least 1 effectiveness follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine in Extension Study</title>
            <description>Represent participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Combined Incidence of HPV 6/11/16/18-related Persistent Infection and HPV 6/11/16/18-related PIN, Genital Warts, and Penile/Perineal/Perianal Cancer in Males</title>
          <description>The HPV types were determined by PCR testing. Combined incidence of HPV 6/11/16/18-related persistent infection and HPV 6/11/16/18-related penile/perineal/perianal intraepithelial neoplasia (PIN), genital warts, and penile/perineal/perianal cancer was assessed in male participants.</description>
          <population>Per-Protocol Effectiveness population: male participants without protocol violations who received at least 1 dose of qHPV vaccine and at least 1 effectiveness follow-up visit.</population>
          <units>Cases per 100 person-years at risk</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.2" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 to Month 30 and Month 30 to Month 126</time_frame>
      <desc>Day 1 to Month 30: All adverse events were collected up to Day 15 after any vaccination. Month 30 to Month 126: Nonserious AEs were not collected. Deaths and related SAEs were collected throughout the study. Non-serious AEs were not solicited during the Extension Study; any reported non-serious AEs were unsolicited and not systematically assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>qHPV Vaccine in Base: Vaccine Phase and Follow-up</title>
          <description>Participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of qHPV at Day 1, Month 2, and Month 6, and had safety follow-up. Adverse events are reported for this group from Day 1 to Month 30.</description>
        </group>
        <group group_id="E2">
          <title>Placebo in Base: Vaccine Phase and Follow-up</title>
          <description>Participants who were randomized into the Placebo Group, who received three 0.5 mL intramuscular injections of placebo vaccine at Day 1, Month 2, and Month 6, and had safety followup.
Adverse events are reported for this group from Day 1 to Month 30.</description>
        </group>
        <group group_id="E3">
          <title>qHPV Vaccine in Base: Extension and Long-term Follow-up</title>
          <description>Participants who received qHPV in the Base Study. No study treatment was administered after Month 6 for these participants. Adverse events are reported for this group from Month 30 to Month 126. Non-serious AEs were not solicited.</description>
        </group>
        <group group_id="E4">
          <title>qHPV Vaccine in Extension: Extension and Long-term Follow-up</title>
          <description>Participants who received placebo in the Base Study and three 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36 in the Extension Study. Adverse events are reported for this group from Month 30 to Month 126. Non-serious AEs were not solicited.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="932"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Tonic clonic movements</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="932"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="918" subjects_at_risk="1165"/>
                <counts group_id="E2" subjects_affected="344" subjects_at_risk="584"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="323" subjects_affected="237" subjects_at_risk="1165"/>
                <counts group_id="E2" events="109" subjects_affected="78" subjects_at_risk="584"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11.0">Injection site pain</sub_title>
                <counts group_id="E1" events="1705" subjects_affected="853" subjects_at_risk="1165"/>
                <counts group_id="E2" events="434" subjects_affected="268" subjects_at_risk="584"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11.0">Injection site swelling</sub_title>
                <counts group_id="E1" events="336" subjects_affected="241" subjects_at_risk="1165"/>
                <counts group_id="E2" events="63" subjects_affected="45" subjects_at_risk="584"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="114" subjects_affected="100" subjects_at_risk="1165"/>
                <counts group_id="E2" events="60" subjects_affected="44" subjects_at_risk="584"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="297" subjects_affected="221" subjects_at_risk="1165"/>
                <counts group_id="E2" events="163" subjects_affected="111" subjects_at_risk="584"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="56" subjects_affected="52" subjects_at_risk="1165"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="584"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The difference between the prior and final data is a minor change in the definition of the per-protocol immunogenicity population, which was applied down to the base study. Also, protocol violators were identified and excluded from the analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

